Multidrug resistant malaria spread under the radar for years in Cambodia

Study suggests that ongoing genomic surveillance is vital to inform malaria control strategies

The most comprehensive genetic study of malaria parasites in Southeast Asia has shown that resistance to antimalarial drugs was under-reported for years in Cambodia. Researchers from the Wellcome Sanger Institute and their collaborators have shown that the parasites developed multidrug resistance to first-line treatments extremely rapidly. They found that one main resistant strain had spread aggressively in the five years before clinical resistance was reported. Delays in detecting the spread of resistance could threaten global efforts to eliminate malaria.

Reported in The Lancet Infectious Diseases, the study suggests that ongoing genomic surveillance is vital to monitor the spread of resistance, to inform public health malaria control strategies.

Malaria is caused by Plasmodium parasites and the World Health Organisation estimated that more than 200 million people were infected and nearly half a million people died worldwide from the disease in 2016*. Children under the age of five are most at risk. Malaria is a treatable disease when caught early enough, but is a huge problem in many areas due to drug resistance.

The first-line treatment for malaria in many areas of the world is a combination of two powerful antimalarial drugs – dihydroartemisinin and piperaquine – otherwise known as DHA-PPQ treatment.

Introduced into Cambodia in 2008, this treatment was initially effective, but in 2013, clinical trials showed that the malaria parasites were resistant to both drugs. Subsequent studies have reported that resistance has since spread to Thailand, Laos and Vietnam.

To help understand future consequences and risks, an accurate picture of the initial emergence and spread of the malaria resistance was needed. Researchers analysed DNA sequence data from nearly 1500 Plasmodium falciparum parasites from Southeast Asia, including more than 450 collected in Cambodia between 2007 and 2013. This allowed them to look back in time to see how the malaria parasites treated with DHA-PPQ evolved resistance.

The genetic study revealed that in the very same year that DHA-PPQ became the official first-line antimalarial treatment in Cambodia, a single multidrug resistant strain of Plasmodium parasite emerged. The researchers found this strain then spread aggressively, outcompeting all the other resistant malaria parasites and leading to complete failure of treatment in Cambodia. Other drugs may be effective at the moment but the situation is extremely fragile.

These findings have significant implications for management of the global health risk associated with the current malaria outbreak.

“Our study has provided the most comprehensive analysis by far of the parasites responsible for the outbreak of drug resistant malaria in Cambodia. It reveals that resistance to the combination therapy appeared almost as soon as that treatment was introduced as the official first line therapy and that it spread steadily and aggressively after that. Various factors allowed the extent of this outbreak to stay under the radar for years, but we show it is now possible to use modern genomic technologies to get a full picture of an outbreak.”

Dr Roberto Amato First author on the paper from the Wellcome Sanger Institute

Drug resistance is spreading across parts of Southeast Asia and experts are unclear how the malaria parasites will respond to current malaria drug treatments.

“This study confirms earlier observations that a strain of malaria, resistant to our most effective drugs, has emerged in the Greater Mekong Subregion. If this parasite strain keeps spreading and becomes dominant further afield it could devastate vulnerable populations globally.

“It is surprising to see that the parasites developed resistance so rapidly. Coordinated actions by governments and organisations to control and eliminate this parasite population are urgently needed. Real-time genetic sequencing would allow regional malaria control programmes to respond immediately to evolutionary changes in the parasite population.”

Professor Mike Turner Head of Infections and Immunobiology at Wellcome

“Our study shows that modern genomic surveillance can detect patterns of resistance much sooner than was possible in the past, providing vital information and allowing public health officials to respond as soon as possible. There is now an urgent need to provide national malaria control programmes with the tools for active genomic surveillance that will help to detect new emergences of resistance as soon as they arise and thereby reduce the risk of a major global outbreak.”

Dominic Kwiatkowski A corresponding author on the paper from the Wellcome Sanger Institute and the University of Oxford

More information

*Figures from the 2017 World Health Organisation report http://www.who.int/malaria/publications/world-malaria-report-2017/en/

What is malaria?

• Spread by mosquitos, malaria is one of the most common infectious diseases and a global public health challenge.
• Malaria is a life-threatening disease caused by a parasite that is transmitted through the bite of infected female Anopheles mosquitoes.
• The parasite that causes malaria is a microscopic, single-celled organism called Plasmodium.
• There are six different species of malaria parasite that cause malaria in humans but Plasmodium falciparum and Plasmodium vivax are the most common types.
• Malaria is predominantly found in the tropical and sub-tropical areas of Africa, South America and Asia.
• It is estimated that there were 198 million cases of malaria in 2013 and 584,000 deaths.
• Around 95% of deaths are in children under the age of five living in Sub-Saharan Africa. However, death rates have fallen globally by 47% since 2000.
• If not detected and treated promptly, malaria can be fatal. However, with the right treatment, started early enough, it can be cured.

For more information about malaria please see http://www.yourgenome.org/facts/what-is-malaria

Funding:

This work was supported by Wellcome (098051, 206194, 090770, 204911); the Bill & Melinda Gates Foundation (OPP1040463, OPP11188166); Medical Research Council (G0600718); UK Department for International Development (M006212) and the Intramural Research Program of the National Institute of Allergy and Infectious Diseases, National Institutes of Health.